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ABSTRACT 
Throughout life bone is constantly renewed to meet the changes deriving from loading forces 
and metabolic needs, via the process of bone remodelling.  An imbalance in bone 
remodelling, in favor to bone resorption, results in loss of bone mass and strength, leading to 
osteoporosis. Multiple factors play a causative role in this process, which include extrinsic 
(losses of sex steroids, excess of exogenous glucocorticoids, lipid oxidation and marrow 
adipogenesis, decreased growth factors) and intrinsic (oxidative stress) mechanisms of cell 
dysfunction. Although these intrinsic mechanisms remain mainly unclear, we hypothesized 
that autophagy, a recycling-lysosome based pathway, may play a critical role in maintaining 
bone cells function and viability and that a decline in autophagy with age may be part of the 
pathogenetic mechanism of age-related skeletal involution.  
The goals of the study proposed here are to investigate the role of autophagy in bone and to 
determine whether loss of autophagy in osteocytes increases their susceptibility to stress, such 
as exogenous glucocorticoids.  
For these purposes, we inactivated autophagy in osteocytes by conditional deletion of Atg7, a 
gene essential for autophagy, and found that osteocyte-specific autophagy deficient mice 
displayed low bone mass and strength, reduced bone turnover and increased oxidative stress. 
Importantly, all these changes were similar to those that occur with age in wild type mice, 
suggesting that a decrease in autophagy may contribute to the degenerating effects of aging on 
the skeleton.  
To establish whether the autophagy pathway helps osteocytes resist stress, mice lacking 
autophagy in osteocytes were treated with glucocorticoids (Prednisolone) or placebo for 28 
day. Our results demonstrate that exogenous glucocorticoids stimulate autophagic flux in 
osteocytes in vivo but lack of autophagy in osteocytes does not accentuate the negative impact 
of glucocorticoids on the skeleton, suggesting that autophagy in this cell type does not appear 
to be an important defence mechanism opposing the negative effects of glucocorticoids on the 
skeleton. In conclusion we demonstrated that experimental inactivation of autophagy in 
osteocytes accelerates skeletal changes associated with aging, but does not accentuate the 
impact of exogenous glucocorticoids on the skeleton. Overall, these findings identify 
autophagy as a critical determinant of bone homeostasis and as an intrinsic mechanism to 
bone cells that contributes to the age-related bone loss, providing a new potential therapeutic 
target in osteoporosis.  
 
 
4 
CHAPTER 1: Introduction 
1.1 Bone biology 
1.1.1 Bone structure and cells of the skeleton 
 
Bone is a connective tissue, physiologically mineralized, that undergoes constantly 
regeneration throughout life by a continual process of bone remodelling. The skeletal system 
consists of calcified cartilage in the growth plate (in growing skeletons), the bone marrow 
cavity, and the mineralized and non-mineralized (osteoid) components of the cortical and 
cancellous bone.  The skeleton functions as a body-framework to sustain the organs, preserve 
skeletal size, shape, and structural integrity and to respond to mechanical forces. Moreover 
the bone acts as an endocrine organ in order to regulate mineral homeostasis. In an adult 
body, bone tissue is composed of 50-70% hydroxyapatite crystals [Ca10(PO4)6(OH)2] enabling 
bone to be a reservoir for these ions and participate in mineral homeostasis; 20-40% organic 
matrix, made up by collagen and non- collagenous proteins, which confers  flexibility; 5-10% 
fluid water that provides mechanical properties and less than 3% lipids 
Bone can be divided into two compartments: trabecular (or cancellous) bone, a sponge-like 
network consisting of myriads of highly interconnected bony trabeculae, and cortical (or 
compact) bone, shaped like a cylinder around the trabecular bone (Fig 1a). 
 
 
 
 
Figure 1a. Three dimensional reconstruction of a mouse tibia in a micro-computed tomography (μCT) 
scan. Epiphysis and diaphysis of long bones are made up of cancellous bones surrounded by a cortex 
of compact bone. 
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Although identical in their chemical composition, the abundance of these two compartments 
varies at different skeletal sites and they can respond differently to metabolic changes, aging 
and therapeutic treatments. 
Bone is continuously forming and being resorbed during growth and in response to 
mechanical or metabolic signals. Three major cell types perform bone remodelling: bone-
resorbing osteoclasts, bone-forming osteoblasts and osteocytes, which are the sensors of bone 
regulating osteoclast and osteoblast formation. 
Osteoclasts are multinucleated cells that resorb bone. They constitute 1-2 % of the bone cells 
and originate from the myeloid/monocyte lineage. Osteoclast formation, differentiation and 
survival are dependent on the activity of two cytokines: macrophage-colony stimulating factor 
(M-CSF) and receptor activator of NF-κB ligand (RANKL). M-CSF binds to its receptor, c-
fms, on osteoclast precursors and activates MAP kinases and ERKs cascades during the early 
phase of differentiation. RANKL binds to its receptor, RANK, on the surface of osteoclast 
progenitors, activating NF-κB, c-Fos, phospholipase Cγ (PLCγ) and nuclear factor of 
activated T cells c1 (NFATc1) signaling to induce differentiation into osteoclasts. Once 
mature osteoclasts are formed, to resorb bone they need to attach to the bone matrix. This 
process requires a profound rearrangement of the cytoskeleton allowing the formation of an 
actin ring surrounded by αvβ3 integrins called podosome. Osteoclasts attach to bone matrix 
via interaction of αvβ3 integrins with Arg-Gly-Asp (RGD) motifs of osteopontin and bone 
sialoprotein in bone matrix (2-4), generating the sealing zone. Nuclei are moved in the 
opposite direction of the sealing zone while lysosomes vesicles containing degrading enzymes 
are transported to the plasma membrane and then here by endocytosis they fuse with the 
plasma membrane, originating the osteoclast specific membrane, the ruffled border. 
Acidification of the resorption lacuna dissolves the mineralized component of bone exposing 
the organic matrix (4;5). The exocytosed resorption enzymes such as Cathepsin K (CatK) and 
matrix metallo-proteases work best in acidic conditions and thus degrade the exposed organic 
matrix in the resorption lacunae  (4;6).  
A mesenchymal progenitor can become an osteoblast cells via sequential activation of two 
transcription factors Runx2 and Osterix. Osteoblastic cells are specialized, terminally 
differentiated cells defined histologically as cuboidal or round-shape cells with enlarged 
Golgi and extensive endoplasmic reticulum, to sustain a high synthetizing activity. 
Osteoblasts under basal conditions constitute ~4-6% of all the bone cells. Osteoblasts are 
recruited in team to the bone surface where they start depositing new bone matrix that 
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undergoes mineralization. At the end of this process some osteoblast will die by apoptosis, 
some will enter a resting phase and acquire a flattened morphology becoming lining cells and 
some will be buried by the mineralized bone matrix and become osteocytes, which are post 
mitotic cells that make up 90 % of the cells in the (7). 
During development osteoblast formation is regulated by several signalling pathways and 
growth factors such as the Indian hedgehog (Ihh), Notch, Wnt, bone morphogenic protein 
(BMP) and fibroblast growth factor (FGF) pathways (8). Ihh pathway is required for 
endochondral bone formation during embryogenesis and postnatal development growth.  
Notch signalling can ether inhibit osteoblast differentiation from early progenitors or 
stimulate late osteoblastic differentiation. Other soluble factors such as IGF-1, FGF23 and 
prostaglandin E2 also participate in postnatal osteoblastogenesis.  
Lining cells have been proposed to play a role in bone remodelling by forming a canopy over 
the area to be remodelled and recruiting osteoclasts.  In addition, recent studies have shown 
that lining cells can transform back into osteoblasts in response to PTH (9). However, due to 
lack of knowledge on lining cell specific gene expression and the difficulty in visualizing 
them in murine bone, knowledge about lining cells and their function is limited (9-12).  
Osteocytes are post-mitotic cells that differentiate from mature osteoblasts, when become 
entrapped in the mineralized matrix (Fig 1b). Osteocytes, entombed in a lacuna, account for 
over 90% of all bone cells. They are dispersed throughout the mineralized bone and establish 
connections to cells on the bone surfaces and with other osteocytes and to blood vessel 
through a network of dendritic process. Osteocytes can live as long as the entire body life 
(13). Because of these peculiar features, osteocytes can be considered as major controller of 
the bone (14). These cells, for a long time considered static residents of the bone tissue 
participate actively in bone homeostasis regulation and can be considered secretory cells. 
Loss-of-function studies where osteocytes specific genes have been deleted, have revealed the 
important roles for osteocytes in skeletal biology. They act as mechanosensors, by receiving 
and responding to mechanical strength and send signals to form and remove bone. Studies in 
mice lacking the RANKL gene specifically in osteocytes (DMP1-Cre;Ranklf/f) demonstrated 
that osteocytes, but not matrix-synthesizing osteoblasts, are the major producers of 
osteoclastogenic cytokine receptor activator of NFκB ligand (RANKL) and regulate 
cancellous osteoclast formation and therefore bone resorption during physiological conditions 
(15;16). Moreover they act as an endocrine organ, regulating phosphate homeostasis via the 
DMP1- FGF23 pathway (17). Moreover, osteocytes produce Sclerostin, the product of the 
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SOST gene, which inhibits WNT signalling and osteoblast differentiation (18). Dysfunctional 
osteocytes may be the culprit in several bone disease such as glucocorticoids-induced skeletal 
fragility, loss of bone during osteoporosis and aging. 
 
 
 
Figure 1b: Osteocytes differentiation. Bone matrix synthetizing osteoblasts (1) differentiate into 
osteoid osteocytes (2). When mineralization of the osteoid is complete, osteocytes become embedded 
and shift their morphology from cuboidal (3,4) to spindle-like shape (5). Adopted from “Primer on the 
Metabolic Bone Diseases and Disorders of Mineral Metabolism, Chapter 4: Osteocytes, p. 35, Eight 
Edition”. 
  
 
 
 
 
 
 
 
 
 
 
1.1.2 Bone remodelling  
 
Throughout life, bone is constantly renewed at numerous sites of the skeleton to meet the 
changes deriving from damage, loading forces and metabolic needs. This process of 
replacement of old bone with new bone is called bone remodelling. Bone remodelling is 
critical for the maintenance of calcium homeostasis and replacement of old or damaged bone 
with newly formed bone. Bone remodelling is performed by teams of osteoblasts and 
osteoclasts organized within transient anatomical structures known as “basic multicellular 
units” (BMUs) Fig. 1c (11;19-26) 
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Figure 1c: Basic Multicellular Unit.  This image depicts a resorbing multinucleated osteoclast, 
followed by a team of osteoblasts, deposing unmineralized bone matrix (osteoid). Buried into the bone 
matrix there are the osteocytes, main players in the regulation of bone remodelling. Courtesy of Robert 
Weinstein 
 
 
In each BMU, teams of osteoblasts follow the resorption front composed of osteoclasts. Bone 
remodelling can be described in distinct and sequential phases: activation, resorption, 
reversal, formation, and termination (Fig. 1d) 
The activation phase requires a signal to target the bone surface for activation of the BMU. 
Several signals can initiate the activity of BMU such as RANKL produced by osteocytes or 
lining cells in response to various stimuli such as mechanical loading, apoptosis of osteocytes, 
microcracks or hormonal action (PTH).  Lining cells are thought to play a role in the initiation 
of the remodeling cycle (19). Evidence support the role of lining in the formation of a 
structure known as canopy, that enclose all the cells and soluble factors needed for bone 
remodelling, keeping local and discrete the remodelling process. Generation of new 
capillaries, recruitment of osteoclast precursors, differentiation and attraction of the pre-
osteoclasts to exposed mineral surface and finally their differentiation into mature osteoclasts 
lead to the formation of resorption front of a BMU. The initiation phase is followed by the 
resorption phase in which mature osteoclasts form tightly sealed resorption compartments on 
bone, acidify these compartments via their proton pumps and secrete lysosomal enzymes such 
as Cathepsin K. As a result, the mineral and organic phases of bone matrix are dissolved by 
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the combined action of low pH and the resorptive enzymes. After resorption, osteoclasts die 
by apoptosis.  
 
 
Figure 1d: Bone remodelling cycle. The sequence of quiescence, resorption, reversal phase, 
formation and mineralization are depicted in this illustration.  Image produced by Biomedical Tissue 
Research (University of York, 
http://www.york.ac.uk/res/bonefromblood/background/boneremodelling.html) 
 
 
 
Under physiologic conditions the work performed by the BMU is spatially and temporally 
regulated.  If there is coupling between formation and resorption, the osteoblastic team will 
appear at the right time and in the right number before osteoclasts have finished to resorb 
bone. This allows the complete reconstitution of the eroded cavity by the osteoblast team and 
so the process of bone remodelling to be balanced. TGF-β and IGF I and II, released during 
bone matrix degradation stimulate recruitment of osteoblast to the resorbed site, thus enabling 
coupling. Another suggested coupling mechanism is signalling by direct contact between 
osteoclasts and osteoblasts via ephrins (24). Recently, osteoclast-secreted factors have been 
discovered to be involved in the regulation of coupling (27). The phase of remodelling in 
which coupling and osteoblast differentiation occur is called the reversal phase (28). The 
reversal phase is followed by the formation and mineralization phase in which new bone is 
formed by osteoblasts and mineralized by the combined actions of osteoblasts and osteocytes 
(28-30).  
Hormonal changes, such as increased PTH or loss of sex steroids, aging not only alter the 
formation of new BMUs, but also affect the life of the cells within BMUs and can thus result 
in negative remodelling balance to favour resorption leading to net bone loss. 
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1.1.3 Skeletal aging 
 
The skeletal tissue is continually regenerated and reshaped to allow the replacement of old or 
damaged bone with new synthetized bone. With aging, the process of bone remodelling 
become unbalanced and osteoblasts fail to keep up with the work performed by the 
osteoclasts; thereby the amount of bone that is deposited at any given time is less than the 
amount of bone that is removed, resulting in a negative balance of the remodelling process 
and therefore in bone loss. Moreover, bone quality decreases with age, affecting bone 
strength. Reduction in bone mass and strength, together with a profound increase in cortical 
porosity make the skeleton more fragile and define one of most common form of metabolic 
disease with old age, known as osteoporosis.  Histologically, reduced wall width, defective 
osteoblast numbers and a decline in osteocyte density characterize aged human bone (14). 
Osteoblasts and osteoclasts are terminally differentiated with a lifespan of weeks or days, 
respectively, while mesenchymal stem cells (MSCs) and osteocytes are long-lived cells. 
Therefore it is reasonable to think that these last cells might be more susceptible than 
osteoblasts or osteoclasts to the age-related changes. Several studies have shown that 
osteocyte numbers and viability decline with age in both rodents and humans (31). Because 
osteocytes control bone resorption by secreting Rankl and osteoprotegerin (15;16;116) and 
bone formation via production of sclerostin (32), a change in the viability of osteocytes 
population might contribute to the age related change in bone remodelling. Halloran and 
colleagues have shown that Rankl and sclerostin levels dropped in bone marrow fluid from 
aged mice (33). However, if a reduction in Rankl explains the drop in osteoclast numbers, the 
reduction in sclerostin does not reconcile with the low osteoblast numbers associated with 
skeletal ageing. Therefore additional mechanisms, perhaps the same mechanisms that occur 
during others degenerative diseases, such as increased levels of oxidative stress or impaired 
protein recycling may affect bone turnover, by decreasing not only the number of osteocytes 
but also their proteostasis. 
Oxidative stress increases with age in bone (34-36). Although cell extrinsic mechanisms 
including loss of estrogens, increased endogenous glucocorticoid levels and higher lipid 
oxidation are associated with the decreased bone formation seen in old age (37), several 
clinical and epidemiological evidences, in both humans and murine models, suggest that 
oxidative stress is a critical determinant for the decrease in bone mass and strength that occur 
with aging and that loss of sex hormones exacerbates the effects of aging on bone, by 
reducing the cellular defence against oxidative stress (37).   
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Reactive oxidative species (ROS) affect the birth and the death of bone cells. ROS are by-
products of the oxidative phosphorylation that takes place into mitochondria. To some extent 
ROS are important for cell metabolism because they act as molecule signal. However, to 
prevent excessive ROS production, cells express several scavenger enzymes, superoxide 
dismutases (SODs) and catalase as well as thiol-containing oligopeptides that counteract the 
negative effect of ROS. Moreover, several transcription factors, including FoxOs and p53, 
have been identified as important defence mechanism against oxidative stress (38-41). It has 
been shown that FoxOs shift the pool of active β-catenin from TCF to FoxO-mediated 
transcription in osteoblasts (42). Consistent with this, FoxOs deletion specifically in 
osteoblast progenitors increases bone mass, suggesting that FoxOs limit the activity of the 
Wnt-β catenin signalling in these cells thereby decreasing bone formation throughout life. 
Pharmacological and genetic studies support the idea that accumulating ROS represents a 
pathophysiological mechanism for age-related osteoporosis. Moreover the balance between 
the amount of intracellular ROS and the antioxidant cellular defence (such as of FoxO 
transcription factors) is critical for bone homeostasis throughout life.  Although the role of 
oxidative stress plays a critical role in the pathogenesis of age-related bone loss, others 
intrinsic cellular mechanisms could contribute to skeletal aging. In a recent review nine 
hallmarks of aging have been described as common pathogenetic mechanisms shared among 
several degenerative disorders, such as Therefore telomere shortening, abnormal protein 
folding and impaired autophagy (43). Aggravation of these mechanisms may be all culprits of 
osteoporosis.  
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1.2 Glucocorticoid-induced bone disease 
 
Glucocorticoids are commonly used in the clinical practice as immunosuppressive and anti-
inflammatory drugs; however their administration is associated with development of 
secondary osteoporosis. 30 to 50% of the patients receiving long-term glucocorticoids therapy 
experience fractures (44).  
Bone loss in response to long-term glucocorticoid therapy occurs in 2 phases: an early, 
transient phase of relatively rapid reduction in bone mineral density (BMD) of 6–12% within 
the first year, and a second phase of slower annual loss of about 3% (45). However, the risk of 
fractures is greater within the first 3 months after initiation of glucocorticoid therapy and this 
often occurs before a significant decline in BMD (46). 
Risk factors of glucocorticoid-induced osteoporosis (GIO) include, among others, advancing 
age, prolonged duration of treatment, and polymorphisms in the glucocorticoid receptor. The 
risk is probably the same in men and women of all ethnicities. Another factor is the activity of 
the 11β-hydroxysteroid dehydrogenase (11β-HSD) system, a pre-receptor modulator of 
corticosteroid action (47).  
Steroid hormones bind to nuclear receptor and, by modifying the allosteric conformation of 
the receptor, induce dimerization of the ligand-receptor complex. The ligand-bound dimeric 
receptor now interacts with the steroid-responsive element region on the DNA and induces 
transcriptional changes of steroid-target genes (transactivation).  
The activity of steroids hormones can be modulated by HSDs enzymes, which act in a pre-
receptor fashion, also known as intracrine modulation. 11β-HSD type 2 functions as a NAD+-
dependent 11β oxidase to convert the active alcohol steroid (cortisol) to the inactive ketone 
glucocorticoid (cortisone). Vice-versa 11β-HSD type 1 acts predominantly as a NADPH-
dependent 11-ketosteroid reductase and converts cortisone to cortisol (48). Increased fractures 
caused by glucocorticoid administration in the elderly may be attributed to the increase in 11 
β-HSD1 that occurs with aging. 
It is known that glucocorticoids exert their negative effects on the skeleton in part via a direct 
action on bone cells, decreasing the production of osteoblasts and increasing the apoptosis of 
osteoblasts and osteocytes while prolonging the lifespan of mature osteoclasts (46). This has 
been proved in a series of studies employing transgenic mice overexpressing the 11β-HSD2 
enzyme, which inactivated glucocorticoids, specifically in osteoblast and osteocytes. As 
results these mice, shielded from the action of glucocorticoids in osteoblast and osteocytes, 
still experienced loss of BMD (due to the action of glucocorticoids on osteoclast) but were 
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protected from the glucocorticoids-induced decrease in bone formation, osteoblast and 
osteocytes apoptosis and loss of strength, suggesting that osteocyte viability independently 
contributes to bone strength (49).  
Using the same approach, overexpressing the 11β-HSD2 in osteoclasts resulted in preserved 
bone mineral density, but did not prevent the prednisolone-induced decrease in osteoblast 
number, osteoid production, and bone formation (50).  
These results support the idea that osteoblast, osteocytes and osteoclasts are direct targets of 
glucocorticoid. 
Histomorphometric analyses in patients with GIO reveal reduced osteoblast number with 
reduced matrix synthetizing activity that leads to decreased osteoid formation, reduced bone 
formation and decreased wall width. Glucocorticoids limit the proliferation and differentiation 
of osteoblast, and cause premature apoptosis of the mature, matrix-secreting osteoblasts. 
Increased osteocyte apoptosis also occurs and is associated with decreased in vascular 
endothelial growth factor (VEGF), skeletal angiogenesis, bone interstitial fluid, and bone 
strength. Thus, glucocorticoid-induced osteocyte apoptosis could account for the loss of bone 
strength that occurs before loss of BMD and the resultant mismatch between bone quantity 
and quality in patients with GIO. Interesting, glucocorticoids stimulate endocortical 
resorption, increasing cortical porosity and thinning of the cortex (51-53). 
Different mechanisms have been proposed to explain how glucocorticoids limit osteoblasts 
activity: they can stimulate the expression of the Wnt antagonist DKK1 (54), and suppressing 
BMP2 and Runx2 (55), both required for osteoblast differentiation. Moreover, glucocorticoids 
increase production of peroxisome proliferator-activated receptor γ, a transcription factor that 
induces terminal adipocyte differentiation while suppressing osteoblast differentiation, 
predisposing mesenchymal stem cells residing in the bone marrow to preferentially 
differentiate into adipocytes, contributing to increased marrow fat and reduced osteoblasts 
(56).   
Studies performed in vitro using human and murine osteoblastic cell line showed that 
glucocorticoids stimulate RANKL expression while down regulate OPG levels (57;57-59). 
However whether this is the case in vivo remains still unknown and requires further 
investigations. Moreover, glucocorticoids could cause increased osteoclast resorption by 
reducing the circulating levels of the RANKL decoy ligand, osteoprotegerin.  Glucocorticoids 
limit the differentiation of osteoclast precursors in new mature resorbing cells but, contrary to 
the effects on osteoblasts, prolong the life span of mature osteoclast by inhibiting their 
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apoptotic death. Therefore cancellous osteoclast numbers in patients receiving glucocorticoids 
treatments are within the normal range or slightly above the baseline.  Furthermore 
glucocorticoids have been shown to impair the resorbing activity of osteoclast by inhibiting 
the M-CSF-induced rearrangement of the cytoskeleton in osteoclasts (60).  
 
 
 
1.3 Autophagy 
1.3.1 Overview 
 
Autophagy is a survival mechanism that operates at basal level in almost all cell types and, in 
response to stress signals, is activated to ensure metabolic activity and viability of cells. Three 
distinct forms of autophagy are commonly described: microautophagy, where cytoplasmic 
content is directly targeted for the lysosome degradation; chaperone-mediated autophagy 
(CMA), where selective individual proteins are degraded by lysosomes upon binding with the 
hsp70-chaperone complex and macroautophagy (hereafter referred to as autophagy) which is 
the most common form of autophagy (61). Autophagy (auto "self" and phagein "to eat”) acts 
a quality control system, via lysosome-based recycling machinery, highly conserved through 
evolution, which has to main functions: to remove unnecessary intracellular contents and to 
build new forms of energy. This is achieved via the sequestration of long-lived proteins, 
damaged organelles and invasive pathogens in double-membrane vesicles called 
autophagosomes, which fuse with lysosomes allowing degradation of the cargo content. The 
products of this breakdown are then recycled back to the cytosol, providing new sources of 
energy to meet the metabolic demand during starvation and other stressful conditions, such as 
lack of growth factors, hypoxia and ER stress. In this way autophagy helps cells to maintain 
their viability, function and homeostasis.  This process appears to be especially important in 
long-lived cells where the clearance of dysfunctional components is crucial for the 
maintenance of health. Impairment of the autophagic process has been shown to contribute to 
the pathogenesis of several diseases, including cancer, metabolic and neurological disorders 
and microbe infection; moreover a decline in autophagy has also been described as one the 
hallmarks of cellular aging (62-66).   
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1.3.2 Mechanisms of autophagy 
 
The autophagy pathway proceeds through distinct steps: vesicle nucleation, elongation, 
docking/fusion of autophagosomes-lysosome, and breakdown of the cargo followed by 
release of the degradation products back into the cytosol (Fig.1e).  
 
 
 
 
Figure 1e: Autophagy pathway. This cartoon depicts the four phase of autophagy: vesicle nucleation, 
elongation, docking and fusion and degradation. Misfolded proteins and others cargo content are 
engulfed by double membrane vesicles and targeted for the lysosomal degradation. From: “Basic 
Biology of Skeletal Aging: Role of Stress response Pathway” J Gerontol A Biol Sci Med Sci 2013 
October; 68(10): 1197–1208. 
 
These steps are orchestrated by different sets of ATG proteins, which constitute the core 
autophagic machinery, highly conserved in eukaryotes, including mammals. Autophagy 
activity under basal conditions is maintained at a low level; therefore, an efficient mechanism 
to induce autophagy is crucial for organisms to adapt to stress and extracellular cues. The 
(mammalian) target of Rapamycin (mTOR), is a negative regulator of autophagy in organisms 
from yeast to man. mTOR is inhibited under starvation conditions, and this contributes to 
starvation-induced autophagy via activation of mTOR target ULKs-Atg13-FIP200, a 
mammalian protein complex that functions as a scaffold for the recruitment of multiple ATG 
proteins to initiate autophagosome formation. 
The source of autophagosome membrane is still debated. One theory support the de novo 
synthesis of autophagosome from a nucleating structure, made of lipids of different origins. 
Another theory explains that the autophagosome originates from the ER, because these two 
structures are found to be in close relation using study of three-dimensional electron 
tomography (67). The nucleation of the phagophore vesicle (autophagosome precursor) 
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requires the class III phosphoinositide 3-kinase (PI3K) Vps34, which acts in a large 
macromolecular complex that also contains Atg6 (also called Beclin 1), Atg14, and Vps15 
(p150). The elongation of membranes, critical step for the autophagosome biogenesis, 
involves two ubiquitin-like conjugation pathways, the Atg12 and Atg8/LC3 systems. 
Atg12 is activated by Atg7 (E1 activating enzyme), transferred to Atg10 (E2 conjugating 
enzyme) and covalently attached to an internal lysine of the substrate protein Atg5. The 
Atg12–Atg5 conjugate further interacts with a coiled-coil protein Atg16, which links the 
Atg12–Atg5-Atg16 complex into a tetramer by self-oligomerization and attaches it to the 
phagophore (68). 
LC3, a mammalian homolog of Atg8, is first processed by a cysteine protease, Atg4, exposing 
a C-terminal glycine residue. The E1 like enzyme Atg7 activates Atg8/LC3 and transfers it to 
Atg3 (E2). In this way LC3 form I, mostly cytosolic, is conjugated to the target lipid PE via 
an amide bond, facilitated by the E3-like Atg12–Atg5 conjugate, to form LC3-II, which now 
is localized to both sides of the phagophore. Of note, Atg7 is indispensable for this this 
conjugation process and genetic inactivation of Atg7 effectively suppresses autophagy (69). 
The lipidation of LC3 is widely used to monitor autophagy induction (70). LC3-positive 
autophagosomes can interact with some substrates in a selective fashion, by binding 
p62/SQSTM1, which recruits ubiquitinated proteins and inclusion bodies, via an ubiquitin-
binding (UBA) domain, mediating the autophagosome cargos recruitment (71). In autophagy 
deficient cells, p62/SQSTM1 accumulates because it cannot be degraded, confirming that it is 
selectively recognized and degraded by autophagy.  
When autophagy is initiated multiple LC3-positive autophagosomes form randomly in the 
cytoplasm, after which they are transported to lysosomes, via microtubules, in a dynein-
dependent manner. At this stage, autophagosome vesicles fuse with lysosomes, generating 
autophagolysosomes. Autophagosome-lysosome fusion appears to be mediated by the 
SNARE proteins, VAMP8 and Vti1B and requires the lysosomal membrane protein LAMP-2 
and the small GTPase Rab7.  After fusion, degradation of the cargo content inside the inner 
vesicle is dependent on lysosomal activity. The resulting small molecules, particularly amino 
acids, are transported back to the cytosol for protein synthesis and maintenance of cellular 
functions under starvation conditions.  
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1.3.3 Physiological and pathological roles of autophagy 
 
The basal role of autophagy is to remove damaged organelles and protein aggregates, limit 
ER stress and ROS generation, in order to ensure cellular fitness and to preserve homeostasis 
of post-mitotic cells throughout life. However, a numbers of studies conducted in global or 
tissue-specific autophagy deficient mice have clearly showed that autophagy participates in 
various physiological roles.  
In mammals, fertilization is a strong inducer of autophagy, which plays an essential role in 
early embryogenesis (72), and global deletion of some ATG genes is embryonically lethal 
(69). Autophagy plays a role during the early phases of body development and it has been 
proposed as an explanation for the phenomenon of maternal inheritance of mitochondrial 
DNA in C. Elegans and, perhaps in mammals (73;74). Autophagy participates in the 
differentiation process of lymphocytes and active secretory cells like erythroid cells and 
adipocytes, which require intense rearrangement of their own cytoskeleton and removal of 
mitochondria (75-79). Autophagy helps to eliminate intracellular microbes, promotes antigen 
presentation and balances the beneficial and detrimental effects of immunity and 
inflammation (80).  
Failure of autophagy to perform its specific functions in adulthood may underlie the 
pathogenesis of certain diseases. Defective autophagy is indeed observed in many human 
diseases (neurodegenerative disease, chronic bacterial and viral infections, atherosclerosis, 
and cancer) (64). Impaired autophagy and the consequent accumulation of prone-protein 
aggregates have been proposed as pathogenic mechanisms in neurodegenerative diseases 
(81;82). Autophagy plays a more complex role in cancer, because it can have a tumour 
suppressor mechanism or promote the progression of the tumour, by contributing to cancer 
cells survival when growth factors are depleted or in response to cancer treatments (83). The 
role of autophagy has also been related to the development of (cardio)myopathy and 
metabolic diseases . 
Furthermore, the correct functioning of the autophagic process has been implicated in 
longevity (84). Autophagy efficient seems to decline with age (85) and experimental 
suppression of autophagy mimics the effect of aging in various tissues (86-89). By avoiding 
accumulation of toxic proteins, autophagy exerts a beneficial effect on cell viability and 
function, which may also be responsible for its longevity-promoting effect (90).  
Interestingly, several treatments or genetic manoeuvres that extend lifespan (caloric 
restriction, sirtuin activation, TOR suppression) are also able to promote autophagy 
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activation, suggesting that various life-prolonging signalling pathways act through 
modulation of autophagy (91;92).  
 
 
 
Fig 1d: Physiological and pathological roles of autophagy. Failure of autophagy to perform its 
specific functions in adulthood may underlie the pathogenesis of certain diseases. The role of 
autophagy in bone is unclear. Image adapted from: Mizushima N, Komatsu M 2011 Autophagy: 
renovation of cells and tissues. Cell 147:728-741 
 
Recent results highlighted a novel and non-canonical role of autophagy, not related to 
lysosomal degradation of autophagosomal contents, which seems to regulate unconventional 
protein secretion. Secreted proteins have a signal peptide or leader sequence, and after 
entering the ER-Golgi route are transported to the plasma membrane via vesicular carriers and 
then secreted. Several studies performed in the last decade have described proteins which 
don’t follow this conventional protein secretion pathway and that don’t have a signal peptide. 
Many unconventional secretion modalities have been described and they can be broadly 
classified into non-vesicular (FG2, MATa, HIV-1 Tat, annexin A2 and FGF1) and vesicular 
(IL- 1β, Acb1 in yeasts) (93). More recently the participation of core autophagic proteins in 
the regulation of protein secretion has been established for the stimulated secretion of Von 
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Willebrand factor in endothelial cells (94), for the release of insulin in pancreatic cells (95), 
for the ROS-induced release of mucin in goblet cells (96). 
How the autophagy machinery contributes to the unconventional secretory pathway remains 
largely unknown, nevertheless compelling evidences suggest that in addition to its canonical 
role in intracellular degradation and recycling, autophagy plays has a critical role in the 
controlled secretion of some proteins in specific cellular types. 
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CHAPTER 2: Significance of the study 
Osteocytes are the longest-lived mature bone cells and are thus the most likely to sustain the 
cumulative damage to their organelles that is responsible for aging and associated diseases. It 
has been shown that osteocyte viability decreases with age in humans and rodents and that 
this is associated with increased oxidative stress, reduced bone vascular volume, decreased 
solute transport in the lacunar-canalicular system and a decrease in bone strength. Osteocytes 
express the cellular machinery for autophagy, a cellular recycling process required for 
adaptation to stress and involved in the survival of long-lived cells.  Because aging is 
associated with the accumulation of damaged cellular components, many have proposed that 
autophagy may decrease or become less efficient with age.  However, the role of autophagy in 
bone and whether autophagy is important to help bone cells to resist stress is unknown. It is 
reasonable to hypothesize that autophagy plays an important role in osteocytes survival and 
function and that its decline might contribute to the age-dependent deterioration of the 
skeleton. Specifically, autophagy may help osteocytes defend against stresses such as elevated 
reactive oxygen species. The goal of the studies proposed here are to determine the role of 
autophagy in osteocytes under physiological and stress conditions. To clarify the state of 
autophagy in osteocytes and to determine whether loss of autophagy in osteocytes increases 
their susceptibility to the negative effects of exogenous glucocorticoids, mice lacking 
autophagy in Dmp1-Cre expressing cells were generated. 
The current study will in part uncover the role of autophagy in bone cells during skeletal 
homeostasis and stress conditions. This may shed light to novel approaches to maintain 
osteocyte function and viability during aging, leading to increased skeletal strength. 
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CHAPTER 3: Autophagy in skeletal homeostasis: role in the osteoblast 
lineage under physiological and stress condition 
 
3.1 Osteocyte autophagy is required for normal bone mass 
 
“This work is an adaptation of a research originally published in Journal of Biological 
Chemistry. Melda Onal, Marilina Piemontese, Jinhu Xiong, Yiying Wang, Li Han, Shiqiao 
Ye, Masaaki Komatsu, Martin Selig, Robert S. Weinstein, Haibo Zhao, Robert L. Jilka, Maria 
Almeida, Stavros C. Manolagas and Charles A. O’Brien. Suppression of autophagy in 
osteocytes mimics skeletal aging. JBC. 2013; 288:17432-17440 © the American Society for 
Biochemistry and Molecular Biology.” 
 
3.1.1 Introduction 
 
The adult skeleton is continuously remodelled by teams of osteoclasts, which resorb bone, 
and teams of osteoblasts, which form new bone (7). Because bone mass declines with age, it 
is clear that the balance between resorption and formation becomes negative with aging. 
Reduced production of sex steroids causes a rise in the rate of bone remodelling that subsides 
with time, but age-associated bone loss occurs even in individuals with normal levels of sex 
steroids (97). Importantly, rodents do not lose estrogens with age, however they do lose bone 
mass, suggesting that mechanisms intrinsic to bone cells contribute to skeletal involution with 
age (34). Although these intrinsic mechanisms remain unclear we hypothesized that 
autophagy, a recycling-lysosome based pathway, may play a critical role in maintaining 
osteocytes function and viability and that a decline in autophagy with age may be part of the 
pathogenetic mechanism of osteoporosis and age-related skeletal involution. 
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3.1.2 Materials and methods 
 
Animal studies. The experimental animals used in most of the studies described here were 
obtained using a two-step breeding strategy.  Hemizygous Dmp1-Cre transgenic mice were 
crossed with heterozygous Atg7-flox mice to generate heterozygous Atg7-flox offspring with 
and without a Dmp1-Cre allele.  These offspring were then intercrossed to generate the 
following offspring: wild type (WT) mice, mice hemizygous for the Dmp1-Cre allele, mice 
homozygous for the Atg7-flox allele, hereafter referred to as Atg7-f/f, and Atg7-f/f mice that 
were also hemizygous for the Dmp1-Cre allele.  For studies requiring larger numbers of mice, 
Atg7-f/f mice were crossed with Atg7-f/f mice that were also hemizygous for the Dmp1-Cre 
allele.  Offspring were genotyped by PCR using the following primer sequences: Cre-for, 5′-
GCGGTCTGGCAGTAAAAACTATC-3′, Cre-rev, 5′-
GTGAAACAGCATTGCTGTCACTT-3′, product size 102 bp; Hind-Fw, 5′-
TGGCTGCTACTTCTGCAATGATGT-3′, Atg7-ex14-F, 5′-
TCTCCCAAGACAAGACAGGGTGAA-3′, Pst-Rv, 5′-
CAGGACAGAGACCATCAGCTCCAC-3′, product size 216 bp (WT) and 500 bp (floxed 
allele).  Both the Dmp1-Cre and Atg7-flox mice were crossed into the C57BL/6 genetic 
background for more than 10 generations prior to initiating generation of mice for this study. 
All studies involving mice were approved by the Institutional Animal Care and Use 
Committees of the University of Arkansas for Medical Sciences and the Central Arkansas 
Veterans Healthcare System.  
 
Oxidative stress and autophagy flux detection. To measure oxidative stress, quantification 
of intracellular reactive oxygen species (ROS) in freshly isolated bone marrow cells from 
tibias was performed using dichlorodihydrofluorescein diacetate dye as previously described 
(98) and quantification of the phosphorylation state of the p66
shc
 protein was done by 
immunoblot in protein lysate from L6 (34). To confirm suppression of autophagy, we 
quantified LC3 conversion and p62 levels in proteins extracted from osteocytes-enriched 
cortical bone. Briefly, proteins were extracted from osteocyte-enriched cortical bone by 
freezing bones in liquid nitrogen followed by pulverization in liquid nitrogen. The pulverized 
bone powder was then incubated in RIPA buffer [50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 
1.0% Igepal CA-630 (NP-40), 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate 
(SDS)] containing 1X SDS-PAGE loading buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 6% 
Glycerol, 1% β-mercaptolethanol and 0.004% bromophenol blue) for 30 minutes in ice, 
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followed by 10 minutes incubation at 100 C. The pulverized bone powder was then spun 
down at 14000 rpm for 10 minutes and the obtained protein supernatant was then resolved in 
12% SDS polyacrylamide gels and electroblotted onto polyvinylidene difluoride membranes. 
Membranes were subsequently blocked with 5% nonfat dry milk in TBS and were then 
incubated with primary antibodies and an appropriate horseradish peroxidase-linked 
secondary antibody. The following antibodies were used: anti-LC3 (Cell Signaling 
Technology, Danvers, MA), anti-p62 (Progen Biotechnik, Heidelberg, Germany), and anti-
tubulin (Sigma-Aldrich, St. Louis, MO). Blots were developed using enhanced 
chemiluminescence and the intensity of the bands was quantified using a ChemDoc XRS-plus 
system (Bio-Rad, Hercules, CA). 
 
Skeletal analysis and histomorphometry. BMD was measured in live mice by dual-energy 
x-ray absorptiometry with a PIXImus Mouse Densitometer (GE Lunar Corp., Madison, WI) 
using the manufacturer's software as described previously (99). Soft tissue was removed from 
femurs or L4 vertebra, which were then store in saline at -20 C until analyzed. Micro-CT 
analysis of cortical and trabecular architecture was performed in femurs and fourth lumbar 
spine, as previously described (100), followed respectively by 3-point bending  and 
compression test, to measure biomechanical properties (53). L1–L3 lumbar vertebrae were 
fixed and embedded undecalcified in methylmethacrylate and static and dynamic 
histomorphometric examination was done on longitudinal sections with a digitizer tablet 
(OsteoMetrics, Inc., Decatur, GA) interfaced to a Zeiss Axioscope (Carl Zeiss, Thornwood, 
NY) with a drawing tube attachment, as previously described (49). Terminology 
recommended by the Histomorphometry Nomenclature Committee of the American Society 
for Bone and Mineral Research was used in this study (101). 
 
 
RNA and genomic DNA isolation and TaqMan assay. For genomic DNA isolation, bone 
pieces were decalcified in 14% EDTA for 1 week after collagenase digestion. Decalcified 
osteocyte-enriched bone was then digested with proteinase K (0.5 mg/ml in 10 mM Tris, pH 
8.0, 100 mM NaCl, 20 mM EDTA, and 1% SDS) at 55° C overnight. Genomic DNA was 
then isolated by phenol/chloroform extraction and ethanol precipitation. For soft tissues, 
approximately 30 mg of tissue was digested with proteinase K and processed in the same way 
as osteocyte-enriched bone. To quantify Atg7 gene deletion, the following custom Taqman 
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assay for exon 14 was used: forward, 5′- ACCAGCAGTGCACAGTGA-3′, reverse, 5′- 
GCTGCAGGACAGAGACCAT-3′, probe, 5′- FAM-CTGGCCGTGATTGCAG-NFQ-3′. 
The custom Atg7 assay was used in combination with a Taqman copy number reference 
assay, Tfrc (catalog number 4458367).  To extract Total RNA, the fifth lumbar spine was 
homogenized in 1ml of Trizol Reagent (Life technology, Grand Island, NY), according 
manufacturer’ instruction. Quantitation and 260/280 ratio of the extracted RNA were 
determined using a Nanodrop instrument. 500 ng of RNA was then used to synthesize first-
strand cDNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies) 
according to manufacturer’s directions. cDNA was  amplified by real-time PCR (RT-PCR) 
using TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA)) as 
described previously (102). The following TaqMan primer-probe sets from Applied 
Biosystems were used: Sost, Mm00470479_m1; Mepe, Mm02525159_s1; RANKL, 
Mm00441908_m1; osteoprotegerin, Mm00435452_m1, tartrate-resistant acid phosphatase, 
Mm00475698_m1; cathepsin K, Mm00484036_m1; osterix-1, Mm00504574_m1; collagen 
1a1, Mm00801666_g1; osteocalcin,  (forward, 5′-GCTGCGCTCTGTCTCTCTGA-3′, 
reverse, 5′-TGCTTGGACATGAAGGCTTTG-3′, probe, 5′-FAM-AAGCCCAGCGGCC-
NFQ-3′); and the house-keeping gene ribosomal protein S2, (forward, 5′-
CCCAGGATGGCGACGAT-3′, reverse, 5′-CCGAATGCTGTAATGGCGTAT-3′, probe, 5′-
FAM-TCCAGAGCAGGATCC-NFQ-3′.  Relative mRNA levels were calculated using the 
ΔCt method (103). To quantify mitochondrial DNA, the following custom Taqman assay for 
the mitochondrial gene ND2 was utilized: forward, 5′-
CATGACAAAAAATTGCTCCCCTATCAA-3′, reverse, 5′-ATGC 
CCCTATGAAAATAGAAGTAATTGCT-3′, probe, 5′-FAM-CCCGCTACTCAACTCT-
NFQ-3′.  The amount of mitochondrial DNA was calculated using results from the ND2 and 
Tfrc copy number reference assays and the ΔCt method (103). 
 
Cell culture.  Bone marrow cells were harvested from long bones and used to quantify 
colony forming units (CFU)-fibroblast (CFU-F), CFU-osteoblasts (CFU-OB), and osteoclast 
progenitors as previously described (104;105).  Osteoblast differentiation of bone marrow 
precursors was evaluated by plating bone marrow cells in 12-well plates at 5×106 cells/well 
and culturing in α-MEM containing 15% fetal bovine serum, 1% 
penicillin/streptomycin/glutamine, 1% ascorbic acid, and 10 mM β-glycerolphosphate.  One-
half of the culture medium was changed every 3 days.  After 21 days, the cultures were fixed 
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with 10% Millonigs modified phosphate buffered formalin and then stained with an aqueous 
solution of 40 mM alizarin red.  After photography, the alizarin red was extracted with 10% 
acetic acid and quantified as previously described (106).  Osteoblast-specific gene expression 
was evaluated in parallel cultures lacking β-glycerolphosphate and harvested after 12 days.  
The ability of bone marrow cells to support osteoclast differentiation was evaluated by plating 
bone marrow cells as above and adding vehicle or 10-7 M parathyroid hormone (PTH) for 12 
days followed by RNA extraction and quantification of osteoclast-specific genes 
 
Apoptosis quantification.  Femurs from 6-month-old female mice were fixed in 10% 
Millonigs modified phosphate buffered formalin for 24 hours, decalcified in 5% formic acid 
and dehydrated in 100% ethylene glycol monoethyl ether, prior to paraffin-embedding and 
sectioning.  Apoptotic osteocytes were detected using TACS® 2 TdT DAB 
(diaminobenzidine) Kit (Trevigen, Gaithersburg, MD). 
 
Transmission Electron Microscopy.  Decalcified bones were placed into fixative (2.5% 
glutaraldehyde, 2.0% paraformaldehyde, 0.025% calcium chloride in a 0.1M sodium 
cacodylate buffer, pH 7.4) and allowed to fix for 3 hours at room temperature.  The bones 
were post fixed with osmium tetroxide, en bloc stained with 2.0% uranyl acetate, dehydrated 
in a graded ethanol series, and embedded in pure epoxy resin.  Thin sections were cut using a 
diamond knife and an LKB 2088 ultramicrotome and placed on copper grids.  Sections were 
stained with lead citrate and examined in a FEI Morgagni transmission electron microscope.  
Images were captured with an AMT 2K digital CCD camera (Advanced Microscopy 
Techniques, Danvers MA). 
 
Statistics. Data were analysed using SigmaStat (SPSS Science, Chicago, IL). We performed 
two-way analysis of variance (ANOVA) or Student’s t-test to detect statistically significant 
treatment effects, after determining that the data were normally distributed (Shapiro-Wilk 
test) and exhibited equivalent variances. In some cases, we used log transformation to obtain 
normally-distributed data. Multiple comparisons were evaluated with Bonferroni or Holm-
Sidak post hoc tests. P-values less than 0.05 were considerate as significant. All values are 
reported as the mean ± S.D. Data that did not pass the normality test were evaluated using the 
Mann-Whitney Rank Sum Test. 
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3.1.3 Results 
 
Suppression of autophagy in osteocytes decreases bone mass.   
 
To directly address the role of autophagy in osteocyte, we generated mice lacking autophagy 
in Dmp1-Cre-expressing cells by crossing Atg7-flox mice with transgenic mice expressing 
the Cre recombinase under the control of Dmp1 regulatory elements, hereafter designated 
Dmp1-Cre mice. The Dmp1-Cre transgene results in recombination in osteocytes and some 
mature osteoblasts (15;107). Atg7, which is an E1-like enzyme, activates an ubiquitin-like 
protein known as LC3, which becomes conjugated to phosphatidyl ethanolamine and is 
required for autophagosome production (108). Importantly, Atg7 is essential for autophagy 
(69). Analysis of genomic DNA extracted from osteocyte-enriched cortical bone revealed a 
75% reduction of the Atg7 conditional allele (Fig. 1A). Direct analysis of LC3 expression in 
protein extracted from bone shafts demonstrated reduced conversion from form I 
(unlipidated) to form II (lipidated) in the conditional knockout mice (Fig. 1B) as well as 
accumulation of p62/sqstm1, a protein frequently elevated in cells with reduced autophagy 
(Fig. 1C). Taken together, these results confirm that autophagy was effectively suppressed in 
osteocytes by deletion of Atg7 using the Dmp1-Cre transgene.  
 
 
 
 
Figure 1: Atg7 deletion suppresses autophagy in osteocytes.  (A) Quantitative PCR of loxP-flanked 
genomic DNA, normalized to a control locus, using genomic DNA isolated from osteocyte-enriched 
femoral cortical bone or the indicated soft tissues (n = 7-9 male 6-month-old mice per group).  (B) 
Immunoblot of LC3 in protein extracted from osteocyte-enriched femoral cortical bone.  The ratio 
LC3-II to LC3-I based on quantification of the bands in the immunoblot is shown on the right (n = 4-6 
male 2-month-old mice per group).  (C) Immunoblot of p62 in protein extracted from osteocyte-
enriched femoral cortical bone.  The intensity of the p62 band normalized to tubulin is shown on the 
right (n = 4 male 2-month-old mice per group).  *P < 0.05 using Student’s t-test.   
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BMD measurement in 6 months old conditional knockout mice revelled low bone mass at all 
skeletal sites compared to control littermates (Fig. 2A). Littermates homozygous for the 
Atg7-conditional allele (Atg7-f/f) or harbouring only the Dmp1-Cre transgene had bone mass 
indistinguishable from wild-type littermates demonstrating the specificity of the bone mass 
phenotype (Fig. 2A). Based on the latter observation, all further analysis was confined to 
Atg7-f/f and Dmp1-Cre;Atg7-f/f littermates. 
Analysis of the skeleton by MicroCT revealed decreased cancellous bone volume in the spine 
and femur (Fig. 2B-D). In addition, cortical thickness was reduced and cortical porosity was 
increased in the femurs of conditional knockout mice (Fig. 2E-F). Consistent with these 
changes in bone mass, biomechanical testing revealed that compression strength was reduced 
in lumbar vertebrae of the conditional knockout mice (Fig. 2G). 
 
 
 
 
 
 
Figure 2:  Low bone mass in Dmp1-Cre;Atg7-f/f mice.  (A)  BMD measured by DEXA in the 
femur, spine, and whole body of wild type (WT), Dmp1-Cre, Atg7-f/f, and Dmp1-Cre;Atg7-f/f 
littermates.   (B) High resolution μCT images of the distal femur and L4 vertebra.  (C) Bone volume 
per tissue volume (BV/TV) of cancellous bone in L4 vertebra.  (D-F) Cancellous BV/TV in the distal 
femur, cortical thickness at the femoral diaphysis, and cortical porosity at the femoral diaphysis.  (G) 
Compression strength (stress) of L4 vertebra.  All values in figure 2 were determined in 6-month-old 
male mice (n = 6-9 mice per group).  *P < 0.05 using two-way ANOVA (A) or Student’s t-test (C-G).   
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Bone turnover is reduced in mice lacking autophagy in osteocytes.  
 
To determine whether changes in bone remodelling might explain the low bone mass of the 
mice lacking autophagy in osteocytes, histomorphometric analysis of lumbar vertebrae was 
performed. Osteoclast number and the extent of bone surface covered by osteoclasts were 
decreased by approximately 50% in the conditional knockout mice (Fig. 3A-B), as were 
osteoblast number and surface (Fig. 3C-D). In line with reduced osteoblast number, the bone 
formation rate was reduced in the conditional knockout mice due to a reduced amount of 
mineralizing surface but no change in the mineral apposition rate (Fig. 3E-H). Reduced wall 
width is a consistent histological finding in aged human and murine bone and reflects the 
reduced amount of work (new bone matrix) performed by teams of osteoblasts (34;109). 
Importantly, wall width was significantly lower in the conditional knockout mice compared 
with control littermates (Fig. 3I). A circulating marker of bone resorption, C-terminal 
telopeptide of type I collagen (CTX), was reduced in the blood plasma of the conditional 
knockout mice, although there was no significant change in the bone formation marker 
aminoterminal propeptide of type I collagen (P1NP) (Fig. 3J-K). Taken together, these results 
demonstrate that 6-month-old mice lacking autophagy in osteocytes exhibit a low rate of bone 
remodelling similar to that observed in aged wild type mice. 
 
 
 
Figure 3:  Dmp1-Cre;Atg7-f/f mice have low bone turnover.  (A-I) Histomorphometric analysis of 
lumbar vertebra 1-3.  (A-B) Osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per 
bone surface (N.Oc/BS).  (C-D)  Osteoblast surface per bone surface (Ob.S/BS) and osteoblast number 
per bone surface (N.Ob/BS).  (E-F)  Bone formation rate per bone surface (BFR/BS) and mineralizing 
surface per bone surface (MS/BS).  (G)  Photomicrographs of calcein-labeled surfaces in vertebral 
cancellous bone.  (H-I) Mineral apposition rate (MAR) and wall thickness (W.Th).  (J-K)  CTX and 
osteocalcin (OCN) measured in blood plasma. *P < 0.05 using Student’s t-test. 
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Autophagy plays an important role in the terminal differentiation of some cell types. For 
example, mice lacking autophagy in erythrocyte progenitors develop severe anemia and die 
by 14 weeks of age (75). To determine whether osteocyte differentiation from osteoblasts was 
altered by suppression of autophagy, we quantified osteocyte density and found that it was 
unchanged in either the cancellous or cortical bone of conditional knockout mice (Fig. 4A). 
Similarly, the percentage of apoptotic osteocytes was not different between genotypes (Fig. 
4B). Consistent with these findings, examination of osteocyte morphology in newly 
embedded and mature osteocytes by electron microscopy showed no obvious changes (Fig. 
4C). Lastly, the expression of osteocyte-specific genes such as Sost and Mepe was not altered 
in the conditional knockout mice (Fig. 4D-E). 
 
 
 
 
 
Figure 4: Osteocyte formation in Dmp1-Cre;Atg7-f/f mice.  (A)  Osteocyte density measured in 
cancellous (canc.) and cortical (cort.) bone of lumbar vertebra 1-3 of 6-month-old male mice (n = 6 
per group).  (B)  Osteocyte apoptosis measured in cancellous (canc.) and cortical (cort.) bone of the 
femur of 6-month-old female mice (6 per group).  (C) TEM images of newly-embedded osteocytes 
(left) or mature osteoctyes (right) in femoral cortical bone from 2-month-old male mice.  bar = 2 μm 
(D-E) Quantitative RT-PCR of Sost and Mepe mRNA in calvaria and tibia shafts from 3-month-old 
male mice (n = 6-11 per group).   
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Figure 5:  Osteoclast and osteoblast differentiation.  (A) Quantitative RT-PCR of RANKL and 
OPG mRNA in calvaria and tibia shafts from 3-month-old male mice (n = 6-11 per group).  (B) 
Osteoclast (OC) progenitor number quantified in bone marrow from 12-month-old female mice (n = 3 
wells per group).  (C)  Quantitative RT-PCR of TRAP and cathepsin K (CatK) in bone marrow 
cultures treated with vehicle or PTH for 11 days to induce osteoclast formation (n = 4 wells per 
group).  (D) CFU-F and CFU-OB in bone marrow cells from 12-month-old female mice (n = 3 
wells/group).  (E) Alzarin Red staining and quantification of primary bone marrow cells cultured for 
21 days in osteoblast differentiation medium (n = 3 wells/group).  (F) Quantitative RT-PCR of osterix-
1 (Osx1), collagen1a1 (Col1a1), and osteocalcin (Ocn) in 12-day primary bone marrow cultures (n = 3 
wells/group).  *P < 0.05 using Student’s t-test.   
 
 
Two studies have recently shown that mice lacking RANKL in osteocytes have reduced 
cancellous bone remodelling due to a reduction in osteoclast formation (15;16). Thus it is 
possible that suppression of autophagy in this cell type altered production of RANKL or its 
soluble decoy receptor osteoprotegerin (OPG) to reduce osteoclast formation in Dmp1-
Cre;Atg7-f/f mice. However, measurement of RANKL and OPG mRNAs in calvarial bone or 
osteocyte-enriched cortical bone did not reveal any changes in expression in conditional 
knockout mice (Fig.5A).  We then examined the osteoclastogenic potential of bone marrow 
progenitors and found that, rather than being reduced, it was slightly elevated in conditional 
knockout mice (Fig. 5B). It is also possible that the support of osteoclastogenesis by bone 
marrow stromal cells may have been altered by deletion of Atg7 in osteocytes. However, 
osteoclast differentiation in primary bone marrow cultures from conditional knockout mice 
was similar to cultures from control mice (Fig. 5C). Similar to the osteoclastogenic potential, 
a small but significant increase in colony forming units that give rise to fibroblasts (CFU-F) 
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and osteoblasts (CFU-OB) in the bone marrow of conditional knockout mice was observed  
(Fig. 5D). In contrast, osteoblast differentiation, as measured by mineralizing nodule 
formation and osteoblast specific gene expression in bone marrow cultures, was not affected 
by deletion of Atg7 in Dmp1-Cre-expressing cells (Fig. 5E-F). Thus the reduced bone 
formation and lack of balance between bone resorption and bone formation in the conditional 
knockout mice is not due to insufficient numbers of osteoblast progenitors or an inability of 
progenitors to differentiate into mature osteoblasts. 
 
Suppression of autophagy in osteocytes increases oxidative stress in bone.  
 
It is known that aging in wild type mice is associated with increased oxidative stress as 
revealed by elevated ROS production in bone marrow cells and increased phosphorylation of 
the p66shc adaptor protein in bone tissue (34). Strikingly, p66shc phosphorylation was 
increased in L6 vertebrae of these mice, compared with control littermates (Fig. 6A). 
Moreover, ROS levels were significantly higher in the bone marrow of conditional knockout 
mice (Fig. 6B). Previous studies have demonstrated that suppression of autophagy increases 
ROS in part by increasing the number of mitochondria (110;111). Consistent with this, 
mitochondrial DNA content in osteocyte-enriched cortical bone was higher in conditional 
knockout mice compared with control littermates (Fig. 6C). These results demonstrate that 
suppression of autophagy in osteocytes is sufficient to increase oxidative stress in the bones 
of young mice to levels normally seen in aged animals, possibly via suppression of 
mitochondrial turnover.  
 
 
 
Figure 6:  Oxidative stress in bone from Dmp1-Cre;Atg7-f/f mice.  (A) Immunoblot of phospho-
p66
shc
 in lumbar vertebra 6 from 3-month-old male mice (n = 5 per group).  (B) ROS in bone marrow 
isolated from tibiae of 3-month-old male mice (n = 5 per group).  (C)  Ratio of mitochondrial:nuclear 
DNA determined by Taqman PCR of DNA isolated from osteocyte-enriched femoral cortical bone of 
6-month-old male mice (n = 7-9 per group  *P < 0.05 using Student’s t-test (A-B) or Mann-Whitney 
Rank Sum test (C).   
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3.1.4 Discussion 
 
All the structural, cellular, and biochemical changes that occur in wild type mice with age, 
were observed in Dmp1-Cre;Atg7-f/f mice at 6 months of age. Thus, experimental 
aggravation of autophagy in osteocytes is sufficient to mimic many of the skeletal changes 
that occur with advanced age in young adult mice.   
Similar to aged mice, the low bone mass must be due to an imbalance between resorption and 
formation such that bone is incompletely replaced in each remodelling cycle. The decrease in 
wall width that occurs in the conditional knockout mice is consistent with this idea. Since the 
Dmp1-Cre transgene is active in at least some matrix-synthesizing osteoblasts, it is possible 
that the skeletal phenotype of the conditional knockout mice is due in part to loss of 
autophagy in these cells. However, osteoblast differentiation and osteoblast gene expression 
in primary bone marrow cultures from Atg7 in Dmp1-Cre-expressing cells were not affected, 
suggesting that the skeletal phenotype is most likely due to suppression of autophagy in 
osteocytes rather than osteoblasts and that suppression of autophagy in osteocytes alters 
production of factors that control osteoclast and osteoblast number. Consistent with this idea, 
osteoclast numbers were reduced in the conditional knockout mice even though osteoclasts or 
their progenitors do not express the Dmp1-Cre transgene so did not undergo Atg7 deletion 
(107). There are several potential mechanisms by which suppression of autophagy in 
osteocytes may control bone remodelling. Suppression of autophagy in other long-lived cell 
types, such as neurons and myocytes, increases the basal rate of apoptosis. However, we did 
not detect any changes in osteocyte number or apoptosis in the conditional knock mice. 
Moreover, since osteocyte apoptosis has been associated with (112), or shown to cause (113-
115), increased osteoclast formation and bone resorption, an increase in osteocyte apoptosis 
would not explain the reduced osteoclast formation in mice lacking autophagy in osteocytes. 
Osteocytes have been shown to control osteoclast formation by producing RANKL and OPG 
and to suppress osteoblast formation by producing sclerostin (15;16;18;116). However, we 
did not detect changes in the expression of mRNAs encoding these factors in osteocytes of the 
conditional knockout mice. Nonetheless, it is possible that autophagy controls production of 
these factors via a non-transcriptional regulation. In support of this idea, autophagy has been 
shown to play an important role in the unconventional (not mediated by the classical 
endoplasmic reticulum/Golgi-dependent pathway) secretion of proteins such as IL-1β and IL-
18 (93;117). Thus it will be important to determine whether suppression of autophagy in 
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osteocytes alters secretion or cell-surface expression of factors that are important for bone 
remodelling such as RANKL, OPG, and sclerostin. It is also possible that previously 
unrecognized factors produced by osteocytes contribute to the low remodelling and bone mass 
caused by deletion of Atg7 in these cells.  
An increase in oxidative stress has been functionally associated with the bone loss caused by 
estrogen-deficiency and has been detected in the bones of aged wild type mice (34;118). 
Thus, the increase in oxidative stress in the bones of mice lacking autophagy in osteocytes 
may contribute to the imbalance between bone resorption and formation. The elevated 
mitochondrial DNA content of the osteocyte-enriched bone suggests that the likely source of 
the elevated ROS is an accumulation of damaged mitochondria in the osteocytes of the 
conditional knockout mice.  We have shown previously that blockade of glucocorticoid action 
on osteoblasts and osteocytes blunts the loss of bone mass and strength caused by aging in 
mice (53). We also noted in those studies that corticosterone levels in the circulation increase 
with age. Together, these results suggested that an increase in endogenous glucocorticoids is 
partially responsible for the decrease in bone mass and strength caused by aging. The results 
of the present study suggest that a decline in osteocyte autophagy may also contribute to the 
adverse effects of age on the skeleton. Recent studies have provided evidence that 
glucocorticoids stimulate autophagy in the MLO-Y4 osteocytic cell line (119). Based on these 
studies, the increased endogenous glucocorticoid levels in aged mice might be expected to 
increase autophagy. However, it is important to note that autophagy is regulated by numerous 
signaling pathways and conditions such that the effects of glucocorticoids alone may not 
predominate in aging mice. Direct comparison of autophagy in osteocytes from young versus 
old mice will be required to determine whether this is the case. Our preliminary attempts to 
measure autophagy in old bone have been hampered by the increase in cortical porosity, and 
thus the presence of other cell types, in osteocyte-enriched bone from old mice (data not 
shown).  It is somewhat surprising that the conversion of matrix-synthesizing osteoblasts to 
osteocytes was not altered by deletion of Atg7 in Dmp1-Creexpressing cells. Osteoblasts and 
recently embedded osteocytes, also known as osteoid osteocytes (13), contain abundant 
endoplasmic reticulum and mitochondria that are progressively reduced as the cells mature 
within mineralized bone. Since autophagy is required for similar reductions in cellular 
components during the maturation of other cell types (75), one might have anticipated altered 
osteocyte morphology or increased cell death when Atg7 was deleted using the Dmp1-Cre 
transgene. However, since this transgene does not become active until the matrix synthesizing 
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stage of osteoblast differentiation, it is possible that even after the Atg7 gene was deleted, 
sufficient Atg7 protein remained to allow autophagy to continue until osteocytes were fully 
formed. This would of course depend on the half-life of the Atg7 protein, which likely varies 
in different cell types and conditions. Nonetheless, it remains possible that the process of 
osteocyte formation may be affected when the Atg7 gene is deleted using Cre driver strains 
that become active at earlier stages of osteoblast differentiation. In summary, the results 
presented herein demonstrate that suppression of autophagy in osteocytes causes skeletal 
changes very similar to those caused by aging and suggest the possibility that reduced 
autophagy may contribute to the detrimental effects of aging on bone mass and strength.   
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3.2 Suppression of autophagy in osteocytes does not accentuate the negative 
impact of glucocorticoids on the skeleton 
 
3.2.1 Introduction 
 
Elevated levels of glucocorticoids have been shown to cause stress in several cell types (120). 
Moreover, the therapeutic use of glucocorticoids, such as Prednisolone, is associated with the 
development of secondary osteoporosis, leading to at least one traumatic fracture in 30-50% 
of patients on steroids therapy (46). Previously studies in mice expressing 11β-hydroxysteroid 
dehydrogenase type 2 (11β-HSD2), an enzyme that inactivates glucocorticoids, specifically in 
osteoblasts and osteocytes, showed that the loss of bone mass and strength caused by 
glucocorticoids is primarily due to a direct effect on bone cells, by reducing osteoblasts 
proliferation and differentiation and by increasing osteoblasts and osteocytes apoptosis (49). 
Moreover, mice where osteoclasts were protected from the action of glucocorticoids (TRAP-
11βHSD2), displayed reduced cancellous osteoclast numbers and were prevented from the 
loss of bone mass, indicating that glucocorticoids act directly on osteoclasts, by prolonging 
their lifespan and inhibiting their apoptosis, to decrease bone mass (50). 
Autophagy is a lysosome-based recycling pathway that degrades intracellular components in 
order to promote cell survival under stressful conditions and to maintain cell homeostasis. 
Specifically, old organelles or unfolded proteins become engulfed by a double membrane 
vesicle called an autophagosome that fuses with lysosomes allowing degradation of the 
contents (121).  In this way autophagy provides new sources of energy and helps cells to 
eliminate damaged organelles such as mitochondria, thereby promoting cell survival, viability 
and function. This role appears to be especially important in long-lived cells and a decline in 
autophagy has been proposed as an explanation for the changes that occur in degenerative 
diseases (64). Important, deletion of genes such as Atg7 completely suppresses the process of 
autophagy (69) allowing one to examine the significant of this pathway in various cell types. 
Deletion of the Atg7 gene in mature osteoblast and osteocytes suppresses autophagy and 
caused changes similar to those that occur with age in wild type mice (34;122;123), 
suggesting that a decrease in autophagy in osteocytes may contribute to skeletal aging. 
Moreover it has been shown that glucocorticoids stimulate autophagy in the MLO-Y4 
osteocytic cell line, and that inhibition of autophagy in this cell type aggravates the effect of 
glucocorticoids on cell viability (119;124). Together these observations suggest the possibility 
that autophagy may oppose the negative actions of glucocorticoids on osteocytes and 
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therefore, in the absence of autophagy, the impact of glucocorticoids on the skeleton might be 
increased. However whether this is the case in vivo is unknown, therefore the goal of the 
present study was to determine whether loss of autophagy in osteocytes in vivo increases the 
negative effects of exogenous glucocorticoids on the skeleton. Our results demonstrate that 
although exogenous glucocorticoids stimulate autophagy in osteocytes in vivo, suppression of 
autophagy in this cell type does not accentuate the negative impact of glucocorticoids on the 
skeleton. 
  
  
3.2.2 Materials and methods 
 
Animal studies.  Mice lacking autophagy in osteoblasts and osteocytes were generated by 
deleting the Atg7 gene, which is essential for autophagy, using a Dmp1-Cre transgene, as 
previously described (89). Six-month-old female conditional knockout mice (Dmp1-
Cre;Atg7f/f) and their control littermates (Atg7f/f), were stratified into four groups according 
to spinal bone mineral density (BMD) and slow-release pellets of placebo or prednisolone (2.1 
mg/kg/day) (Innovative Research of America, Sarasota, FL) were implanted subcutaneously.  
After 28 days, a second BMD measurement was performed and then animals were sacrificed 
to analyse the impact of exogenous glucocorticoids on the skeleton. All animal 
experimentations described in the present work were conducted in accord with the 
Institutional Animal Care and Use Committees of the University of Arkansas for Medical 
Sciences.  
 
Oxidative stress and autophagy flux detection. For oxidative stress measurements, we 
performed quantification of intracellular reactive oxygen species (ROS) levels in freshly 
isolated bone marrow cells from tibias using dichlorodihydrofluorescein diacetate dye (98) 
and quantification of the phosphorylation state of the p66
shc
 protein by immunoblot from L6 
(34). To confirm suppression of autophagy and to determine the effect of prednisolone on 
autophagy, we quantified LC3 conversion and p62 levels in proteins extracted from 
osteocytes-enriched cortical bone. Proteins were extracted from osteocyte-enriched cortical 
bone by freezing in liquid nitrogen followed by pulverization in liquid nitrogen. The 
pulverized bone powder was then incubated in RIPA buffer [50 mM Tris-HCl, pH 8.0, 150 
mM NaCl, 1.0% Igepal CA-630 (NP-40), 0.5% sodium deoxycholate, and 0.1% sodium 
dodecyl sulfate (SDS)] containing 1X SDS-PAGE loading buffer (50 mM Tris-HCl, pH 6.8, 
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2% SDS, 6% Glycerol, 1% β-mercaptolethanol and 0.004% bromophenol blue) for 30 
minutes in ice, followed by 10 minutes incubation at 100 C. The pulverized bone powder was 
then spun down at 14000 rpm for 10 minutes and the obtained protein supernatant was then 
resolved in 12% SDS polyacrylamide gels and electroblotted onto polyvinylidene difluoride 
membranes. Membranes were subsequently blocked with 5% nonfat dry milk in TBS and 
were then incubated with primary antibodies and an appropriate horseradish peroxidase-linked 
secondary antibody. 
The following antibodies were used: anti-LC3 (Cell Signaling Technology, Danvers, MA), 
anti-p62 (Progen Biotechnik, Heidelberg, Germany), and anti-tubulin (Sigma-Aldrich, St. 
Louis, MO). Blots were developed using enhanced chemiluminescence and the intensity of 
the bands was quantified using a ChemDoc XRS-plus system (Bio-Rad, Hercules, CA). 
 
Micro computed tomography (μCt), biomechanical testing and histomorphometry. 
Micro-CT analysis of cortical and trabecular architecture was performed in femurs and fourth 
lumbar spine, as previously described (100), followed respectively by 3-point bending  and 
compression test, to measure biomechanical properties (53). L1–L3 lumbar vertebrae were 
fixed and embedded undecalcified in methylmethacrylate and static and dynamic 
histomorphometric examination was done on longitudinal sections with a digitizer tablet 
(OsteoMetrics, Inc., Decatur, GA) interfaced to a Zeiss Axioscope (Carl Zeiss, Thornwood, 
NY) with a drawing tube attachment, as previously described (49). Tibias were fixed in 10% 
Millonig’s formalin for 24 hours, decalcified in 14% EDTA for 1 week, and embedded in 
paraffin to obtained 5 μm longitudinal sections. After removal of paraffin and rehydration, 
sections were stained for TRAP activity and counter-stained with fast green and osteoclasts 
were enumerated on the endocortical surface. Terminology recommended by the 
Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral 
Research was used in this study (101). 
 
TaqMan assay. Osteocytes-enriched bone shafts were prepared by cutting off the epiphysis 
and flushing out the bone marrow. The bone samples were then scraped several times along 
the outer and inner surface to remove osteoblasts and other cells in order to obtain an 
osteocytes-enriched preparation. The cortical bone shafts were then homogenized in 1ml of 
Trizol Reagent (Life technology, Grand Island, NY) to extract Total RNA, according 
manufacturer’ instruction. Quantitation and 260/280 ratio of the extracted RNA were 
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determined using a Nanodrop instrument. 500 ng of RNA was then used to synthesize first-
strand cDNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies) 
according to manufacturer’s directions. cDNA was  amplified by real-time PCR (RT-PCR) 
using TaqMan Universal PCR Master Mix (Applied Biosystems) as described previously 
(102). The following TaqMan primer-probe sets from Applied Biosystems were used: 
calcitonin receptor (Mm00432271_m1); osteoprotegerin (Mm00435452_m1), and the house-
keeping gene ribosomal protein S2, (forward, 5′-CCCAGGATGGCGACGAT-3′, reverse, 5′-
CCGAATGCTGTAATGGCGTAT-3′, probe 5′-FAM-TCCAGAGCAGGATCC-NFQ-3′). 
Gene expression was calculated using the delta Ct method (103) and the ribosomal protein S2 
(ChoB) was used as internal control gene. 
 
Statistics. Data were analysed using SigmaStat (SPSS Science, Chicago, IL). We performed 
two-way analysis of variance (ANOVA) or Student’s t-test to detect statistically significant 
treatment effects, after determining that the data were normally distributed (Shapiro-Wilk test) 
and exhibited equivalent variances. In some cases, we used log transformation to obtain 
normally-distributed data. Multiple comparisons were evaluated with Bonferroni or Holm-
Sidak post hoc tests. P-values less than 0.05 were considerate as significant. All values are 
reported as the mean ± S.D. Data that did not pass the normality test were evaluated using the 
Mann-Whitney Rank Sum Test. 
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3.2.3 Results 
 
Glucocorticoids stimulate autophagy in osteocytes in vivo.  
To determine whether glucocorticoids control osteocyte autophagy in vivo and whether 
autophagy helps osteocytes resist the negative effects of glucocorticoids, we compared the 
impact of glucocorticoid administration on the skeleton of mice with and without functional 
autophagy in osteocytes. Mice lacking autophagy in osteocytes were generated by crossing 
mice harbouring a conditional allele of Atg7 with Dmp1-Cre transgenic mice, which express 
the Cre recombinase primarily in osteocytes. We have shown previously that this approach 
deletes Atg7 from bone but not soft tissues and that it significantly reduces autophagic flux in 
osteocytes in vivo (89). In the current study, 6-month-old female Dmp1-Cre;Atg7f/f mice, 
hereafter referred to as conditional knockout mice, or control littermates (Atg7f/f) were 
implanted with pellets releasing placebo or prednisolone (2.1 mg/kg/day), maintained for 28 
days, and then euthanized for further analysis. 
To confirm suppression of autophagy in osteocytes in the present study, we measured the 
levels of LC3 and p62 by immunoblot analysis.  LC3 is a docking protein that is incorporated 
into growing autophagosome membranes.  This incorporation requires lipidation of the 
protein, which can be monitored on immunoblots by conversion of the unlipidated form I to 
the lipidated form II.  p62 is a scaffolding protein that brings cargos to the autophagosome for 
degradation and can accumulate when autophagy is suppressed (125). Comparison of 
conditional knockout and control mice implanted with placebo pellets revealed that deletion 
of Atg7 from Dmp1-Cre-expressing cells inhibited conversion of LC3 and caused 
accumulation of p62 (Figure 1A-B) in osteocyte-enriched cortical bone, findings which are 
consistent with our previous report (89). 
We then compared autophagic flux in the four groups of mice and found that prednisolone 
stimulated LC3 conversion osteocyte-enriched cortical bone of Atg7f/f mice but not in 
conditional knockout mice (Fig. 1A).  Therefore this result supports the idea that 
glucocorticoids stimulate autophagic flux in osteocytes in vivo.  An increase in autophagic 
flux can also lead to reduced abundance of p62 (126).  Therefore, the stimulation of 
autophagy in Atg7f/f mice by prednisolone might be expected to reduce p62 levels in 
osteocyte-enriched bone.  However, prednisolone did not alter p62 levels in Atg7f/f mice or 
conditional knockout mice (Fig. 1B). 
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Figure 1: Deletion of ATG7 in Dmp1-Cre expressing cells suppresses autophagy and 
Prednisolone stimulates osteocytes autophagy in vivo. Protein lysates extracted from osteocytes-
enriched tibia shafts of females conditional knockout mice or control littermates (n=7 animal per 
group) implanted with placebo or 2.1/mg/day of Prednisolone, were subjected to immunoblot to detect 
LC3 (A) and p62 (B). The intensity of the LC3-I and LC3-II bands was quantified and plotted as the 
ratio of LC3-II to LC3-I. P62 expression was quantified and normalized to tubulin. *p <0.05 effect of 
treatment within genotype; # p <0.05 effect of genotype within treatment. 
 
 
 
Suppression of autophagy in osteocytes does not accentuate the negative impact of 
glucocorticoids on the skeleton. 
We have shown previously that suppression of autophagy in osteocytes results in reduced 
cortical thickness, increased cortical porosity, and low cancellous bone volume and that these 
changes are associated with reduced bone strength (89). In the present study we observed 
similar effects of autophagy suppression in osteocytes in the placebo-treated mice, with the 
exception that cancellous bone volume was not lower in the femurs of conditional knockout 
mice (Fig. 2A-G). However, despite the presence of these changes in the conditional knockout 
mice under basal conditions, administration of prednisolone reduced cortical thickness and 
bone strength and increased cortical porosity to similar extents in the femurs of both Atg7f/f 
controls and conditional knockout mice (Fig 2B-D).  Prednisolone also reduced cortical 
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thickness in L4 vertebra (Fig. 2F) but did not alter bone strength at this site (Fig. 2G).  
Administration of prednisolone did not alter cancellous bone volume or architecture in either 
the femur (Fig. 2A) or L4 vertebra (Fig 2E and 3A-D) of either genotype, findings that are 
consistent with our previous observations. 
 
 
 
Figure 2: Suppression of autophagy in osteocytes does not accentuate the negative impact of 
glucocorticoids on the skeleton. 6 month-old females Dmp-1Cre;Atg7f/f mice (CKO) and control 
Atg7f/f littermates (Ctrl) (n=9-11 per group) were implanted with placebo or Prednisolone pellets for 
28 days and bone architecture was analysed in femoral midshaft  and spine by μCT. Bone 
Volume/Total Volume (BV/TV) of femur (A) and spine (E); Femoral (B) and spinal (F) cortical 
thickness; femoral strength measured by 3-point bending test in femur (C) and compression test in 
spine (G) and expressed in Newton. (D) Cortical porosity of femoral midshaft. *p <0.05 effect of 
treatment within genotype; # p <0.05 effect of genotype within treatment. 
 
 
 
Figure 3: Administration of prednisolone did not alter cancellous bone volume or architecture, 
but suppression of autophagy reduces trabecular bone parameters and strength in fourth 
lumbar vertebra. Trabecular number (A); trabecular thickness (B); trabecular separation (C) and (D) 
strength of fourth lumbar vertebra expresses as maximum compressive stress at the breaking point in 
megapascals (MPa) 
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We have previously shown that prednisolone administration increases oxidative stress in bone 
as measured by Reactive Oxygen Species (ROS) levels in the bone marrow and by 
phosphorylation of the redox sensitive protein p66
shc
 in the bone protein lysates (127). In 
addition we have shown that deletion of the Atg7 gene in osteocytes increases oxidative stress 
as measured by these same parameters (89), which we confirmed in the placebo treated mice 
in this experiment (Fig. 4H and 4I). However, despite the elevated level of oxidative stress in 
the conditional knockout mice under basal conditions, prednisolone increased oxidative stress 
by a similar magnitude in both genotypes (Fig. 2H-I). Together these results indicate that 
suppression of autophagy in osteocytes does not aggravate the changes in cortical structure or 
the increase in oxidative stress caused by prednisolone. 
 
 
 
 
Figure 4: Suppression of autophagy does not further increase oxidative stress in prednisolone 
treated mice. Quantification of Reactive Oxygen Species in the bone marrow normalized to protein 
contents (E) and p66 phosphorylation in whole bone lysate extracted from L6 and normalized to β-
actin (I).  n= 5-6 animals per group. *p <0.05 effect of treatment within genotype; # p <0.05 effect of 
genotype within treatment. 
 
 
Cellular changes induced by Prednisolone were not worse in the absence of autophagy.  
Even though prednisolone did not alter cancellous bone volume (Fig. 2A and 2E), others and 
we have shown that it consistently reduces osteoblast number and bone formation in this 
skeletal compartment (49;128).  Therefore, we examined the effects of prednisolone 
administration and suppression of autophagy, both separately and combined, on the histology 
of cancellous bone of the spine.  Similar to what we observed in our previous study, 
suppression of autophagy in osteocytes reduced the overall rate of bone remodelling.  
Specifically, osteoblast and osteoclast (number and surface), mineralizing surface and bone 
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formation rate were all lower in placebo-treated conditional knockout mice compared to 
placebo-treated Atg7f/f mice, with no change in MAR (Fig. 5A-G).  Consistent with our 
previous findings in wild type mice (33), administration of prednisolone had no impact on 
osteoclast number or surface in cancellous bone in either genotype (Fig. 5C and 5D).  In 
contrast, prednisolone dramatically reduced osteoblast number, surface and bone formation 
rate in Atg7f/f mice but did not further reduce the already low osteoblast number and bone 
formation rate in conditional knockout mice (Fig. 5A-B and 5E and 5G). 
 
 
 
 
Figure 5: Cellular changes induced by Prednisolone were not worse in the absence of autophagy. 
Static and dynamic histomorphometric analyses were performed in lumbar vertebra 1–3, from 6-month 
old CKO and control mice (n=5 per group). (A)Osteoblast number per bone perimeter (Ob.N/B.Pm); 
(B) osteoblast surface per bone surface (OcS/BS); (C) osteoclast number per bone perimeter 
(OcN/B.Pm) and (D) osteoclast surface per bone surface (OcS/BS). (E) Mineralizing surface per bone 
surface (MS/BS), (F) Mineral Apposition Rate (MAR) and (G) Bone Formation Rate (BFR). *p <0.05 
effect of treatment within genotype; # p <0.05 effect of genotype within treatment. 
 
 
 
 
Because prednisolone reduced cortical thickness and increased cortical porosity, we also 
examined osteoclast number at the endocortical surface of the tibia.  In contrast to cancellous 
bone, suppression of autophagy in osteocytes did not change osteoclast number at the 
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endocortical surface. Importantly prednisolone administration significantly increases 
osteoclast numbers at the endocortical surface in both genotypes, as shown by the 
quantification of the TRAP stained tibia sections (Fig 6A-B). Consistent with these results, 
Calcitonin receptor mRNA levels, measured in osteocytes enriched bone shafts, were 
significantly increased by Prednisolone in both genotypes (Fig. 6C). Interesting, these 
changes were associated with a similar suppression of osteoprotegerin expression by 
Prednisolone in osteocytes-enriched bone from both genotypes (Fig. 6D), with no change in 
RANKL expression (data not shown). Thus, glucocorticoids-induced cortical bone loss due to 
stimulation of endocortical resorption was associated with suppression of osteoprotegerin 
RNA levels in osteocytes, and loss of autophagy in this cell type did not worsened this 
response.  
 
 
 
 
 
Figure 6: Prednisolone stimulates endocortical resorption and down regulates OPG mRNA 
levels in osteocytes. (A) Histological sections of tibia were stained for TRAP activity (osteoclasts 
stained red) and counterstained in fast green (original magnification 20X) and osteoclast number 
(Oc.N/B.Pm) and surface (Oc.S/BS) were counted on the endocortical surface starting from the region 
under the primary spongiosa. (B) Calcitonin Receptor (Cal.R.) and Osteoprotegerin (OPG) mRNA 
levels in osteocytes-enriched tibia shafts were measured by RT-PCR (n = 4–6 animals/group). *p 
<0.05 effect of treatment within genotype; # p <0.05 effect of genotype within treatment. 
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3.2.4 Discussion 
 
Autophagy is a stress-activated response that removes and recycles damaged components in 
order to maintain cellular health and viability. Impaired or dysfunctional autophagy has been 
related to different conditions, such as neurological and metabolic disorders, cancer and several 
studies have highlighted the causative effect of autophagy decline on aging (65;85;121). We 
have recently proposed that a decline of autophagy in osteocytes may contribute to skeletal 
aging (89). By deleting the Atg7 gene using a Dmp-1Cre promoter, we have efficiently 
suppressed autophagy in osteocytes.  This manoeuvre led to mice with low bone mass, low 
bone remodelling and increased oxidative stress. A similar phenotype was obtained when a 
ULK-interacting protein required for autophagosome generation, FIP200, was deleted using 
different osteoblast Cre drivers, leading to mice with osteopenia (129). 
Endogenous glucocorticoids levels increase with age, contributing to the decrease of bone 
mass and strength (53); elevated levels of glucocorticoids are known to be deleterious for 
osteoblasts and osteocytes because induce their apoptosis and stimulate the production of 
oxidative stress (52).  Here we show that, based on the quantification of LC3 turnover, 
cortical osteocytes in control mice are able to activate the autophagic process when exposed to 
Prednisolone for 28 days. p62 levels depend on autophagy turnover (22) and when autophagy 
is activated p62 degradation increases. This did not occur in conditional knockout mice under 
basal conditions. It is possible that the presence, in the cortical bone of Prednisolone treated 
mice, of elevated number of osteoclastic cells, which have abundant levels of p62 in their 
cytoplasm, may have masked the decrease in p62, expected with stimulation of autophagy. 
Previous studies have shown that Dexamethasone treatment activates autophagy in 
lymphocytes (130) and in the MLO-Y4 osteocytic cell line. In this last study, the authors 
reported activation of autophagy and antioxidant related genes by Dexamethasone and that 
impairment of autophagy aggravates the effect of Dexamethasone on osteocytes viability in 
vitro (119;130). More recently, autophagy impairment has been shown to enhance the 
deleterious effects of high glucose in an osteoblastic cell line, by increasing oxidative stress 
(131). Because osteocytes are post-mitotic cells trapped in the bone matrix (13), misfolded 
proteins and old organelles cannot be removed through cell division and therefore it is 
reasonable to think that in this cell type autophagy may help to maintain viability and 
function, by limiting the metabolic stress that accumulates with age. To test this hypothesis 
we stressed mice that lacked autophagy in osteocytes with an excess of glucocorticoids and 
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found that loss of bone mineral density as well as the cortical changes, the decrease in 
strength and the increase in oxidative stress caused by Prednisolone were not further 
aggravated compared to mice with an intact autophagic response. Consistent with this, the 
cellular changes induced by Prednisolone were not affected by loss of autophagy, concluding 
that autophagy in osteocytes doesn’t play a major protective role opposing the negative effects 
of glucocorticoids on the skeleton. 
We reported that mice lacking autophagy in Dmp-1Cre expressing cells under basal condition 
do not display an increase in the numbers of apoptotic osteocytes compared to control mice, 
indicating that cell viability is not compromised (89). Yet, it is still possible that in response 
to stressful signals, such as in the presence of an excess of glucocorticoids, cells lacking 
autophagy may become more susceptible and therefore die more. However changes in 
osteocytes apoptosis would not be relevant, given that none of the skeletal and cellular effects 
produced by Prednisolone administration was worsened in the absence of autophagy. 
Several studies have shown that some of the autophagy-related proteins can function in 
processes not related to autophagy. For instance proteins without a leader peptide cannot enter 
the canonical ER-Golgi route for the translocation to the plasma membrane and subsequent 
secretion; therefore they are secreted through alternative pathways, such as the 
unconventional protein secretion pathway (93;132;133). Several types of unconventional 
secretion have been described, that allow cargos to directly pass the plasma membrane (FGF2, 
Annexin 2, HIV-Tat) or in conjunction with vesicle-like structure (IL-1β, IL-18, yeast acyl–
coenzyme A (CoA) binding protein Acb1,nuclear protein HMGB1 and engrailed 
homeoprotein), which requires autophagy related organelles (134). A non-autophagic function 
has been described for several Atg proteins and LC3 protein, involved in the regulation of the 
secretion process in bone resorbing osteoclasts and in the formation of the ruffled border of 
the same cells (135). Moreover, recently autophagy has been found to be responsible for the 
stimulated-secretion of the Von Willebrand factor in endothelial cells (94) and that impaired 
autophagy affects the secretion of insulin from pancreatic beta cells (95;136), supporting a 
new, non-canonical functional role of autophagy. Given these observations, it is possible that 
the negative effects on the skeleton caused by Prednisolone are not aggravated in the absence 
of autophagy because autophagy in osteocytes might have additional functions, such as the 
regulation of secretion and trafficking of factors important for bone homeostasis and that the 
increase in autophagy that occurs in osteocytes after Prednisolone administration might be 
unrelated to his recycling and protective role. 
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Cortical and trabecular bone compartments have been shown to behave differently in response 
to aging, hormonal signals and mechanical stimulations (34;137;138). Prednisolone, at the 
dose and time used in this experiment, profoundly affected the cortical compartment, in either 
femur or spine, but did not cause cancellous bone loss, as observed in the control mice. 
Although osteoclast numbers on the trabecular surface of Prednisolone treated mice were in 
the normal range, they might not have been fully functional. It has been shown that 
glucocorticoids administration can impair osteoclastic bone resorption, by inhibiting the 
rearrangement of osteoclast cytoplasm in the presence of M-CSF (60). Therefore the 
inhibition of bone formation together with the impaired bone resorption could explain why 
mice didn’t lose cancellous bone after prednisolone treatment.  
More interesting for the glucocorticoids-induced bone disease, we found, for the first time to 
our knowledgem that Prednisolone down regulated transcripts levels of osteoprotegerin in 
osteocytes-enriched bone in vivo. Our data are consistent with previous in vitro finding 
showing that glucocorticoids down regulated OPG mRNA levels in human osteoblastic cells 
(139;140), in the MLO-Y4 osteocytic cell line (141) and that circulating levels of 
osteoprotegerin are diminished in patients treated with glucocorticoids (142). This result, 
together with the increase in endocortical resorption, supports the hypothesis that a reduction 
in osteoprotegerin in osteocytes may be responsible for the glucocorticoid-induced bone 
disease, by enhancing bone resorption. However we cannot rule out that the observed increase 
in endocortical resorption was due to a direct effect of glucocorticoids on osteoclasts (7), and 
further studies are required to establish whether this is a direct or indirect effect and which are 
the underlying molecular mechanisms. Nevertheless, as observed for all the other skeletal and 
cellular changes, the reduction in osteoprotegerin mRNA levels that occurs in osteocytes in 
response to an excess of glucocorticoids is not made worse by suppression of autophagy. 
In summary these results demonstrate that exogenous glucocorticoids stimulate autophagy in 
osteocytes in vivo, suppression of autophagy does not accentuate the negative impact of 
glucocorticoids on the skeleton and that glucocorticoids-induced bone disease occurs 
independently of autophagy function. Thus we conclude that although glucocorticoids are able 
to stimulate autophagy in osteocytes, autophagy in osteocytes does not appear to be an 
important defence mechanism opposing the negative effects of glucocorticoids on the 
skeleton.  
CHAPTER 4: Conclusion and future work 
 
Although researchers have recently gained new insights into the role of autophagy in skeletal 
homeostasis (119;129;135), the significance of this pathway in bone tissue remains mainly 
unclear. In the present study we carried out experiments to investigate the role of autophagy 
in osteocytes and mature osteoblasts and determine whether loss of autophagy in this cell 
types increase their susceptibility to the negative effects of exogenous glucocorticoids. To do 
this, we generated mice lacking autophagy specifically in osteocytes and mature osteoblasts, 
using the Dmp1-Cre transgene. Suppression of the Atg7 gene, essential for autophagy, in 
mature osteoblast and osteocytes decreased bone mass and strength and recapitulated the 
effect of skeletal aging. These data identify autophagy as an important determinant of bone 
development and reveal a novel role of autophagy in osteoblast and osteocytes function. 
We also hypothesize that autophagy may oppose the negative actions of glucocorticoids on 
osteocytes and therefore, in the absence of autophagy, the impact of glucocorticoids on the 
skeleton might be increased.  However, even though glucocorticoids stimulate autophagic 
flux in osteocytes in vivo, suppression of autophagy does not aggravate the negative impact of 
exogenous glucocorticoids on the skeleton.  
In conclusion, this study tried to elucidate the role of autophagy in bone, in physiological and 
stress conditions. We suggest that autophagy is required to maintain normal bone mass and 
that experimental aggravation of autophagy in osteocytes accelerates skeletal aging. 
Furthermore, we conclude that autophagy does not appear to be a major mechanism helping 
osteocytes to resist glucocorticoids-induced stress.  Identification of the molecular 
mechanisms underlying the low and unbalanced bone remodelling caused by suppression of 
autophagy in osteocytes will further clarify the role of autophagy in bone.  We have observed 
an increase in mitochondrial DNA content and oxidative stress with age and in autophagy-
deficient osteocytes. Thereby it is possible that suppression of autophagy may determine a 
decrease in bone mass via increasing oxidative stress. To test this hypothesis we will 
overexpress an antioxidant enzyme into the mitochondria of autophagy deficient mice and 
determine whether this blunts the increase in oxidative stress and the decrease in bone mass. 
If we obtain these or similar results, we will conclude that autophagy plays an important role 
in maintaining osteocyte viability, possibly by suppressing oxidative stress. 
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One other line of evidence suggests that autophagy may be implicated in the secretion of 
proteins that do not follow the conventional ER-Golgi route (Unconventional protein 
secretion). It is possible therefore that the low bone mass phenotype may be due to a 
decreased ability of osteocytes to produce and/or secrete mediators such as RANKL, OPG 
and sclerostin that control bone remodeling. To further investigate this option, a more 
extensive and comprehensive analysis of the proteome of conditional knockout mice could 
indicate whether there is a specific protein that has been profoundly affected by loss of 
autophagy or whether conditional knockout mice have in general altered secretion ability, in 
line with data that support a role for autophagy in protein trafficking and secretion. 
Recent evidences suggest that autophagy may be important for the long-term health of 
progenitors. Specifically, deletion of Atg7 from hematopoietic stem cells (HSCs) in mice 
causes mitochondria accumulation and increased oxidative stress, which was associated with 
increased proliferation and DNA damage (143). These results suggested that autophagy 
regulates the maintenance of the HSC compartment in adult mice. Another study has shown 
that HSC display basal levels of autophagy and that this cell type can mount a robust 
autophagy response to survive under stressful conditions, such as nutrient deprivation (144). 
Therefore we will also expand our analysis to other cells types such mesenchymal progenitors 
and the entire osteoblast lineage. Based on these and our initial findings in mice lacking 
autophagy in osteocytes, it is possible that autophagy may play a similar role in the 
maintenance, survival and function of earlier stages of osteoblast-lineage cells and that 
change in autophagy may underlie changes in progenitor’s behavior with age. 
Although the molecular mechanisms underlying such phenotypes are still not fully understood 
and further mechanistic studies are required, it is clear that an impairment of autophagy 
process mimics the skeletal changes that occur during age, identifying autophagy as one 
possible contributor to the age-related bone loss and providing a new potential therapeutic 
target in osteoporosis. 
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